 | Up a level |
Eichhorst, B., Arriola, E., Cerri, E., Verdugo, M., Letschert, K., Mourgues, X., Boughan, S., Pena, G., Wittig, B., Selenko-Gebauer, N., Schuh, A. and Ysebaert, L. (2017). Venetoclax for chronic lymphocytic leukemia: baseline characteristics and safety data from pre-approval cohort programs in the EU. Oncol. Res. Treat., 40. S. 140 - 141. BASEL: KARGER. ISSN 2296-5262
Stilgenbauer, S., Chyla, B., Eichhorst, B., Schetelig, J., Munir, T., Hillmen, P., Seymour, J. F., Roberts, A. W., Coutre, S., Jurczak, W., Mulligan, S. P., Puvvada, S., Wendtner, C-M, Davids, M., Boeettcher, S., Cerri, E., Zhou, L., Popovic, R., Poteracki, M., Arzt, J., Kim, S. Y., Verdugo, M., Bhathena, A., Wierda, W. and Hallek, M. (2017). VENETOCLAX IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION: OUTCOME AND MINIMAL RESIDUAL DISEASE FROM THE FULL POPULATION OF THE PIVOTAL M13-982 TRIAL. Haematologica, 102. S. 311 - 313. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078